Baillie Gifford & CO Bei Gene, Ltd. Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Baillie Gifford & CO holds 3,705,756 shares of BGNE stock, worth $706 Million. This represents 0.64% of its overall portfolio holdings.
Number of Shares
3,705,756
Previous 3,681,949
0.65%
Holding current value
$706 Million
Previous $525 Million
58.38%
% of portfolio
0.64%
Previous 0.42%
Shares
30 transactions
Others Institutions Holding BGNE
# of Institutions
250Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.01 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.23 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$986 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$948 Million0.84% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.7MShares$514 Million0.07% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...